Innoviva, Inc. (INVA)
NASDAQ: INVA · IEX Real-Time Price · USD
17.19
+0.08 (0.47%)
At close: Jul 19, 2024, 4:00 PM
17.21
+0.02 (0.12%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Innoviva Employees
Innoviva had 112 employees as of December 31, 2023. The number of employees increased by 11 or 10.89% compared to the previous year.
Employees
112
Change (1Y)
11
Growth (1Y)
10.89%
Revenue / Employee
$2,782,054
Profits / Employee
$1,619,545
Market Cap
1.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 112 | 11 | 10.89% |
Dec 31, 2022 | 101 | 96 | 1,920.00% |
Dec 31, 2021 | 5 | 0 | - |
Dec 31, 2020 | 5 | -1 | -16.67% |
Dec 31, 2019 | 6 | 0 | - |
Dec 31, 2018 | 6 | -6 | -50.00% |
Dec 31, 2017 | 12 | -2 | -14.29% |
Dec 31, 2016 | 14 | 1 | 7.69% |
Dec 31, 2015 | 13 | 3 | 30.00% |
Dec 31, 2014 | 10 | -231 | -95.85% |
Dec 31, 2013 | 241 | 15 | 6.64% |
Dec 31, 2012 | 226 | 4 | 1.80% |
Dec 31, 2011 | 222 | 29 | 15.03% |
Dec 31, 2010 | 193 | -1 | -0.52% |
Dec 31, 2009 | 194 | 3 | 1.57% |
Dec 31, 2008 | 191 | -120 | -38.59% |
Dec 31, 2007 | 311 | 26 | 9.12% |
Dec 31, 2006 | 285 | 15 | 5.56% |
Dec 31, 2005 | 270 | 24 | 9.76% |
Dec 31, 2004 | 246 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Owens & Minor | 22,200 |
Artivion | 1,500 |
Silk Road Medical | 474 |
Autolus Therapeutics | 463 |
Arcutis Biotherapeutics | 296 |
Ironwood Pharmaceuticals | 267 |
Calliditas Therapeutics AB (publ) | 217 |
Collegium Pharmaceutical | 197 |
INVA News
- 4 weeks ago - Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs - Benzinga
- 6 weeks ago - Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Innoviva to Participate in the BofA Securities Health Care Conference - Business Wire
- 3 months ago - Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 - Business Wire
- 4 months ago - Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 5 months ago - Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress - Business Wire
- 5 months ago - 10 stocks you can bet on being inflation-proof - Market Watch